Aratana Therapeutics Files for First U.S. FDA Approval with AskAt Compound, A Targeted Therapeutic Intended for Control of Pain and Inflammation in Dogs with Osteoarthritis


January 25, 2016 – Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that it filed an administrative New Animal Drug Application (NADA) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for Galliprant® for control of pain and inflammation in dogs with osteoarthritis. The Animal Drug User Fee Act (ADUFA) date for approval is set for March 25.


Galliprant® is an EP4 antagonist (grapiprant, AT-001, AAT-007, RQ-00000007) currently owned by AskAt Inc. (AskAt), a life sciences research and development company based in Nagoya, Japan. As described in Aratana’s announcement: Galliprant® is a new chemical entity and first-in-class piprant product intended to control pain and inflammation associated with osteoarthritis in dogs by binding to the EP4 prostaglandin receptor antagonist on the PGE2 pathway.


AskAt acquired the compound in 2013 from RaQualia Pharma Inc. (RaQualia), after Aratana licensed it in 2010 for worldwide animal health applications. AskAt will share development milestone payments and royalty payments from Aratana with RaQualia.

For more information, please see the Aratana homepage at


About AskAt
AskAt is a new kind of life sciences company, an open collaboration catalyst, with a core team of highly dedicated and experienced professionals from all phases of pharmaceutical research and development. AskAt accelerates innovation in small molecule R&D, designing optimized platforms to deliver enhanced value in life-cycle partnering opportunities around its core intellectual property. AskAt’s R&D programs are focused on areas of critical, unmet patient needs, including cancer, Alzheimer’s Disease, pain, autoimmune disorders, and blindness caused by macular degeneration.

For more information, please contact us at